Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism

John Fanikos, Allison E. Burnett, Charles E. Mahan, Paul P. Dobesh

Research output: Contribution to journalReview article

Abstract

Because differences in renal function can affect the efficacy and safety of direct oral anticoagulants, prescribing an appropriate dose based on renal function is critical, especially in patient populations with a high incidence of renal impairment. In patients with nonvalvular atrial fibrillation and mild or moderate renal impairment, direct oral anticoagulants are associated with a better risk–benefit profile compared with warfarin. However, less is known regarding outcomes in patients with venous thromboembolism and renal impairment. The efficacy and safety of direct oral anticoagulants in patients with venous thromboembolism and renal impairment are primarily derived from prespecified subgroup analyses of the phase 3 clinical trials. We summarize the available data on direct oral anticoagulant use in patients with venous thromboembolism and renal impairment. Clinicians are encouraged to follow study inclusion/exclusion criteria and perform renal dose adjustments based on the Cockcroft–Gault equation using actual body weight when indicated to avoid adverse events.

Original languageEnglish (US)
Pages (from-to)1137-1143
Number of pages7
JournalAmerican Journal of Medicine
Volume130
Issue number10
DOIs
StatePublished - Oct 2017

Fingerprint

Venous Thromboembolism
Anticoagulants
Kidney
Therapeutics
Safety
Phase III Clinical Trials
Warfarin
Atrial Fibrillation
Body Weight
Incidence
Population

Keywords

  • Direct oral anticoagulants
  • Renal
  • Venous thromboembolism

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism. / Fanikos, John; Burnett, Allison E.; Mahan, Charles E.; Dobesh, Paul P.

In: American Journal of Medicine, Vol. 130, No. 10, 10.2017, p. 1137-1143.

Research output: Contribution to journalReview article

Fanikos, John ; Burnett, Allison E. ; Mahan, Charles E. ; Dobesh, Paul P. / Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism. In: American Journal of Medicine. 2017 ; Vol. 130, No. 10. pp. 1137-1143.
@article{7fac184ed096447191afa5f610211ec1,
title = "Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism",
abstract = "Because differences in renal function can affect the efficacy and safety of direct oral anticoagulants, prescribing an appropriate dose based on renal function is critical, especially in patient populations with a high incidence of renal impairment. In patients with nonvalvular atrial fibrillation and mild or moderate renal impairment, direct oral anticoagulants are associated with a better risk–benefit profile compared with warfarin. However, less is known regarding outcomes in patients with venous thromboembolism and renal impairment. The efficacy and safety of direct oral anticoagulants in patients with venous thromboembolism and renal impairment are primarily derived from prespecified subgroup analyses of the phase 3 clinical trials. We summarize the available data on direct oral anticoagulant use in patients with venous thromboembolism and renal impairment. Clinicians are encouraged to follow study inclusion/exclusion criteria and perform renal dose adjustments based on the Cockcroft–Gault equation using actual body weight when indicated to avoid adverse events.",
keywords = "Direct oral anticoagulants, Renal, Venous thromboembolism",
author = "John Fanikos and Burnett, {Allison E.} and Mahan, {Charles E.} and Dobesh, {Paul P.}",
year = "2017",
month = "10",
doi = "10.1016/j.amjmed.2017.06.004",
language = "English (US)",
volume = "130",
pages = "1137--1143",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism

AU - Fanikos, John

AU - Burnett, Allison E.

AU - Mahan, Charles E.

AU - Dobesh, Paul P.

PY - 2017/10

Y1 - 2017/10

N2 - Because differences in renal function can affect the efficacy and safety of direct oral anticoagulants, prescribing an appropriate dose based on renal function is critical, especially in patient populations with a high incidence of renal impairment. In patients with nonvalvular atrial fibrillation and mild or moderate renal impairment, direct oral anticoagulants are associated with a better risk–benefit profile compared with warfarin. However, less is known regarding outcomes in patients with venous thromboembolism and renal impairment. The efficacy and safety of direct oral anticoagulants in patients with venous thromboembolism and renal impairment are primarily derived from prespecified subgroup analyses of the phase 3 clinical trials. We summarize the available data on direct oral anticoagulant use in patients with venous thromboembolism and renal impairment. Clinicians are encouraged to follow study inclusion/exclusion criteria and perform renal dose adjustments based on the Cockcroft–Gault equation using actual body weight when indicated to avoid adverse events.

AB - Because differences in renal function can affect the efficacy and safety of direct oral anticoagulants, prescribing an appropriate dose based on renal function is critical, especially in patient populations with a high incidence of renal impairment. In patients with nonvalvular atrial fibrillation and mild or moderate renal impairment, direct oral anticoagulants are associated with a better risk–benefit profile compared with warfarin. However, less is known regarding outcomes in patients with venous thromboembolism and renal impairment. The efficacy and safety of direct oral anticoagulants in patients with venous thromboembolism and renal impairment are primarily derived from prespecified subgroup analyses of the phase 3 clinical trials. We summarize the available data on direct oral anticoagulant use in patients with venous thromboembolism and renal impairment. Clinicians are encouraged to follow study inclusion/exclusion criteria and perform renal dose adjustments based on the Cockcroft–Gault equation using actual body weight when indicated to avoid adverse events.

KW - Direct oral anticoagulants

KW - Renal

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85028298456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028298456&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2017.06.004

DO - 10.1016/j.amjmed.2017.06.004

M3 - Review article

C2 - 28687262

AN - SCOPUS:85028298456

VL - 130

SP - 1137

EP - 1143

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 10

ER -